Safety Monitoring Committee (SMC) reviewed safety of the first cohort of TEW-7197 and decided to escalate to the next dose.
Oct 21, 2014MILESTONESHit 570
On 14th of Oct. 2014 (13th in USA) SMC reviewed safety of the first cohort of TEW-7197 (NCT02160106) and did not find any drug-related toxicity. The committee recommended a dose escalation to the next level. Three clinical sites in the USA started recruitment of patients with solid tumor for the second cohort.
|Previous||Clinical trial of TEW-7197 starts its first step.|
|Next||MedPacto Announces Clinical Collaboration with MSD to Evaluate Vactosertib, an Investigational TGF-β Type I Receptor Inhibitor, in combination with KEYTRUDA® (pembrolizumab)|